Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för AT-1015 hydrochloride monohydrate. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

8 träffar

Bibliografisk träff 2003-06-01

Insurmountable antagonism of AT-1015, a 5-HT2 antagonist, on serotonin-induced endothelium-dependent relaxation in porcine coronary artery.

Rashid M, Nakazawa M, Nagatomo T.

J Pharm Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1211/002235703765951447

Bibliografisk träff 2003-05-13

The effects of 5-hydroxytryptamine 5-HT2 receptor antagonists on nerve conduction velocity and endoneurial perfusion in diabetic rats.

Cameron NE, Cotter MA.

Naunyn Schmiedebergs Arch Pharmacol · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1007/s00210-003-0750-3

Bibliografisk träff 2002-08-01

AT-1015, a newly synthesized 5-HT2 receptor antagonist, dissociates slowly from the 5-HT2 receptor sites in rabbit cerebral cortex membrane.

Rashid M, Watanabe M, Nakazawa M, Nagatomo T.

J Pharm Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1211/002235702320266299

Bibliografisk träff 2001-12-01

Antithrombotic activity of AT-1015, a potent 5-HT(2A) receptor antagonist, in rat arterial thrombosis model and its effect on bleeding time.

Kihara H, Koganei H, Hirose K, Yamamoto H, Yoshimoto R.

Eur J Pharmacol · journal article · DOI 10.1016/s0014-2999(01)01432-7

Bibliografisk träff 2001-11-01

Assessment of affinity and dissociation ability of a newly synthesized 5-HT2 antagonist, AT-1015: comparison with other 5-HT2 antagonists.

Rashid M, Watanabe M, Nakazawa M, Nakamura T, Hattori K, Nagatom T.

Jpn J Pharmacol · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1254/jjp.87.189

Bibliografisk träff 2001-10-01

Binding affinity of a newly synthesized 5-HT2 antagonist, AT-1015 (N-[2-[4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-piperidino]ethyl]-1-formyl-4-piperidinecarboxamide monohydrochloride monohydrate), in the rabbit platelet membrane.

Rashid M, Watanabe M, Nakazawa M, Nagatomo T.

Biol Pharm Bull · research support, non-u.s. gov't; journal article · DOI 10.1248/bpb.24.1188

Bibliografisk träff 2000-09-01

Inhibitory effects of a newly synthesized 5-HT2 receptor antagonist, AT-1015 (N-[2-[4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)piperidino]-ethyl]-1-for myl-4-piperidinecarboxamide monohydrochloride monohydrate), on contraction and relaxation of pig coronary arteries induced by 5-HT and alpha-methylserotonin: comparison with ketanserin.

Gong H, Rashid M, Nakamura T, Hattori K, Nakazawa M, Kihara H, Yoshimoto R, Nagatomo T.

Biol Pharm Bull · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1248/bpb.23.1105

Bibliografisk träff 2000-04-01

AT-1015, a novel serotonin (5-HT)2 receptor antagonist, blocks vascular and platelet 5-HT2A receptors and prevents the laurate-induced peripheral vascular lesion in rats.

Kihara H, Hirose K, Koganei H, Sasaki N, Yamamoto H, Kimura A, Nishimori T, Shoji M, Yoshimoto R.

J Cardiovasc Pharmacol · journal article · DOI 10.1097/00005344-200004000-00002